Synosia Therapeutics Raises $29 Million
Synosia Therapeutics, a Swiss drug developer focused on psychiatry and neurology, has raised CHF 32 million ($29m) in Series B funding. Aravis Venture and Investor Growth Capital co-led the round, and was joined by Swiss Helvetia Fund and return backers Versant Ventures, Abingworth, Novo A/S and 5am Ventures.
7 January 2009•3 mins read
